Clinical trial · Interventional
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
A Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
NCT03792750CI-TRIAL-00056777completedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-986205 | Drug | — | UNRESOLVED |
| Nivolumab | Biological | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental Arm A
- description
- 2 week BMS-986205 monotherapy lead in followed by BMS-986205 + Nivo combination therapy
- interventionNames
- Drug: BMS-986205
- Biological: Nivolumab
Primary outcomes (15)
- measure
- The Number of Participants Experiencing Adverse Events (AE)
- timeFrame
- From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
- description
- The number of participants experiencing adverse events (AEs) to assess the safety and tolerability of BMS-986205. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
- measure
- The Number of Participants Experiencing Serious Adverse Events (SAE)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants must have histologic or cytological confirmation of a solid tumor that is advanced with measureable disease per RECIST v1.1 * Participants must have received, and then progressed or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting * Participants must have an ECOG performance status of less than or equal to 1 * Participants must have at least 1 lesion with measurable disease as defined by RECIST Version 1.1 Exclusion Criteria: * Participants must not have suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease * Participants with prior exposure to anti PD-1 or anti-PDL1 therapy * Participants must not have a history of allergy to any of the study treatment components
References
Publications (0)
Data not yet available
No reference posted for this study.